At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Lenvima and Keytruda with chemotherapy did not significantly improve OS in metastatic ESCC compared to Keytruda and chemotherapy alone. Median OS was 17.6 months in the Lenvima arm versus 15.5 months ...

Dose interruptions of LENVIMA, KEYTRUDA, or both due to an adverse reaction occurred in 78% of patients receiving LENVIMA in combination with KEYTRUDA. LENVIMA was interrupted in 73% of patients and ...

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma Promega MSI technology will aid in the ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic hepatocellular carcinoma (HCC) as Keytruda (pembrolizumab) plus Lenvima (lenvatinib), ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA ® (pembrolizumab), Merck’s ...